GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Study Finds Calcium Supplements Do Not Reduce Preeclampsia Risk During Pregnancy

by GOAI
Share To

A recent study conducted by researchers at Stellenbosch University has presented substantial evidence suggesting that calcium supplementation during pregnancy does not lower the risk of preeclampsia. The findings, derived from large-scale clinical trials, challenge previous assumptions about the benefits of calcium intake for pregnant individuals in preventing this condition.

The research team analyzed data from multiple extensive trials to assess the impact of calcium supplements on preeclampsia, a serious pregnancy complication characterized by high blood pressure and potential damage to organs such as the liver or kidneys. Despite earlier recommendations promoting calcium supplementation as a preventive measure, the results indicate no significant reduction in preeclampsia risk among those who took calcium supplements during pregnancy. These findings contribute to an ongoing discussion within the medical community regarding effective strategies for managing and mitigating risks associated with maternal health conditions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top